samedan logo
 
 
spacer
home > pmps > autumn 2014 > life line
PAY PER VIEW SERVICE

 

Dear guest!

article: Life Line
format: Adobe Acrobat PDF file
cost: £

spacer

 
News and Press Releases

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed Using Nouscom’s Proprietary Viral Vector Platform

BASEL, Switzerland – 17th May 2022 - Nouscom, a clinical stage immuno-oncology company developing both off-the-shelf and personalized cancer neoantigen immunotherapies, today announced that Janssen Research & Development, LLC (Janssen) received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) candidate VAC85135, an off-the-shelf, viral vector-based cancer vaccine for an oncologic indication. VAC85135 has been exclusively licensed to Janssen.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement